1. Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern.
- Author
-
Akache, Bassel, Renner, Tyler M., Stuible, Matthew, Rohani, Nazanin, Cepero-Donates, Yuneivy, Deschatelets, Lise, Dudani, Renu, Harrison, Blair A., Gervais, Christian, Hill, Jennifer J., Hemraz, Usha D., Lam, Edmond, Régnier, Sophie, Lenferink, Anne E. G., Durocher, Yves, and McCluskie, Michael J.
- Subjects
SARS-CoV-2 Delta variant ,IMMUNE response ,VACCINE effectiveness ,SARS-CoV-2 - Abstract
Using our strongly immunogenic SmT1 SARS-CoV-2 spike antigen platform, we developed antigens based on the Beta & Delta variants of concern (VOC). These antigens elicited higher neutralizing antibody activity to the corresponding variant than comparable vaccine formulations based on the original reference strain, while a multivalent vaccine generated cross-neutralizing activity in all three variants. This suggests that while current vaccines may be effective at reducing severe disease to existing VOC, variant-specific antigens, whether in a mono- or multivalent vaccine, may be required to induce optimal immune responses and reduce infection against arising variants. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF